Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users.
Adult
Buprenorphine
/ administration & dosage
Delayed-Action Preparations
/ administration & dosage
Female
Heroin Dependence
/ drug therapy
Humans
Induction Chemotherapy
/ methods
Injections
Male
Middle Aged
Narcotic Antagonists
/ administration & dosage
Psychotropic Drugs
/ therapeutic use
Substance Withdrawal Syndrome
/ diagnosis
Treatment Outcome
Journal
The American journal on addictions
ISSN: 1521-0391
Titre abrégé: Am J Addict
Pays: England
ID NLM: 9208821
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
29
08
2019
revised:
16
01
2020
accepted:
16
02
2020
pubmed:
14
3
2020
medline:
29
12
2020
entrez:
14
3
2020
Statut:
ppublish
Résumé
Highly potent synthetic opioids (HPSO) are increasingly responsible for opioid overdose deaths in the United States. In an open-label, uncontrolled trial to test the feasibility of extended-release buprenorphine (BXR) injection treatment of heroin-using individuals with opioid use disorder testing positive for HPSO, participants were enrolled and began an induction with sublingual BXR (n = 5). During the induction, ancillary medications (clonidine, clonazepam, zolpidem, and prochlorperazine) were provided for breakthrough opioid withdrawal symptoms. Two participants received the BXR injection on the second day of the induction and three participants on the third day. All five participants were retained at least 1-month postinduction. It may be feasible to provide BXR treatment to HPSO-positive heroin users rapidly to achieve clinical stabilization. (Am J Addict 2020;00:00-00).
Sections du résumé
BACKGROUND AND OBJECTIVES
Highly potent synthetic opioids (HPSO) are increasingly responsible for opioid overdose deaths in the United States.
METHODS
In an open-label, uncontrolled trial to test the feasibility of extended-release buprenorphine (BXR) injection treatment of heroin-using individuals with opioid use disorder testing positive for HPSO, participants were enrolled and began an induction with sublingual BXR (n = 5). During the induction, ancillary medications (clonidine, clonazepam, zolpidem, and prochlorperazine) were provided for breakthrough opioid withdrawal symptoms.
RESULTS
Two participants received the BXR injection on the second day of the induction and three participants on the third day.
DISCUSSION AND CONCLUSION
All five participants were retained at least 1-month postinduction.
SCIENTIFIC SIGNIFICANCE
It may be feasible to provide BXR treatment to HPSO-positive heroin users rapidly to achieve clinical stabilization. (Am J Addict 2020;00:00-00).
Identifiants
pubmed: 32167629
doi: 10.1111/ajad.13018
pmc: PMC7383940
mid: NIHMS1611380
doi:
Substances chimiques
Delayed-Action Preparations
0
Narcotic Antagonists
0
Psychotropic Drugs
0
Buprenorphine
40D3SCR4GZ
Types de publication
Case Reports
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
345-348Subventions
Organisme : NIDA NIH HHS
ID : K24 DA029647
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007294
Pays : United States
Organisme : NIDA NIH HHS
ID : U54 DA037842
Pays : United States
Informations de copyright
© 2020 American Academy of Addiction Psychiatry.
Références
Drugs. 2017 May;77(7):747-763
pubmed: 28337672
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358
pubmed: 29596405
J Clin Psychopharmacol. 2016 Feb;36(1):18-26
pubmed: 26650971
Neuropharmacology. 2018 May 15;134(Pt A):121-132
pubmed: 29042317
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Eur J Pharmacol. 1992 Mar 24;213(2):219-25
pubmed: 1355735
J Pain. 2014 Dec;15(12):1215-26
pubmed: 25441689
Clin Pharmacol Ther. 1980 Jul;28(1):106-14
pubmed: 7389247
J Clin Pharmacol. 2016 Jul;56(7):806-15
pubmed: 26479717